Biology of Blood and Marrow Transplantation
Volume 14, Issue 5 , Pages 499-509 , May 2008

The Allogeneic Effect Revisited: Exogenous Help for Endogenous, Tumor-Specific T Cells

  • Heather J. Symons

      Affiliations

    • Division of Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    • Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    • ,
  • Moshe Y. Levy

      Affiliations

    • Division of Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    • Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    • ,
  • Jie Wang

      Affiliations

    • Division of Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    • ,
  • Xiaotao Zhou

      Affiliations

    • Division of Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    • ,
  • Gang Zhou

      Affiliations

    • Division of Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    • ,
  • Sarah E. Cohen

      Affiliations

    • Thomas Jefferson Medical College, Philadelphia, Pennsylvania
    • ,
  • Leo Luznik

      Affiliations

    • Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    • ,
  • Hyam I. Levitsky

      Affiliations

    • Division of Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    • Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    • ,
  • Ephraim J. Fuchs

      Affiliations

    • Division of Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    • Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
    • Corresponding Author InformationCorrespondence and reprint requests: Ephraim Joseph Fuchs, MD, 488 Blunting-Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231

Received 2 July 2007 ,Accepted 11 February 2008.

References 

  1. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–1073
  2. Weiden PL, Flournoy N, Sanders JE, Sullivan KM, Thomas ED. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplant Proc. 1981;13(Pt 1):248–251
  3. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987;2:175–178
  4. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  5. Kolb HJ. Graft-versus-leukemia effects of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  6. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–444
  7. Tsukada N, Kobata T, Aizawa Y, Yagita H, Okumura K. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood. 1999;93:2738–2747
  8. Schmaltz C, Alpdogan O, Horndasch KJ, et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood. 2001;97:2886–2895
  9. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15:1767–1777
  10. Drobyski WR, Klein J, Flomenberg N, et al. Superior survival associated with transplantation of matched unrelated versus 1-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood. 2002;99:806–814
  11. O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–386
  12. Dey BR, McAfee S, Colby C, et al. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol. 2005;128:351–359
  13. Colvin GA, Lambert J-F, Lum LG, et al. Effective universal outpatient immunotherapeutic approach for refractory acute myelocytic leukemia: HLA-haploidentical transplants in 100 cGy-conditioned hosts. [abstract] Blood. 2002;100:636a
  14. Strair RK, Schaar D, Medina D, et al. Antineoplastic Effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma. J Clin Oncol. 2003;21:3785–3791
  15. Kondo M, McCarty MF. Rationale for a novel immunotherapy of cancer with allogeneic lymphocyte infusion. Med Hypotheses. 1984;15:241–277
  16. Alexander P, Delorme EJ, Hall JG. The effect of lymphoid cells from the lymph of specifically immunized sheep on the growth of primary sarcomata in rats. Lancet. 1186–1189.
  17. Ellman L, Katz DH, Green I, Paul WE, Benacerraf B. Mechanisms involved in the antileukemic effect of immunocompetent allogeneic lymphoid cell transfer. Cancer Res. 1972;32:141–148
  18. Katz DH, Ellman L, Paul WE, Green I, Benacerraf B. Resistance of guinea pigs to leukemia following transfer of immunocompetent allogeneic lymphoid cells. Cancer Res. 1972;32:133–140
  19. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol. 1979;122:549–554
  20. Levitsky HI, Montgomery J, Ahmadzadeh M, et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol. 1996;156:3858–3865
  21. Fuchs EJ, Matzinger P. B cells turn off virgin but not memory T cells. Science. 1992;258:1156–1159
  22. Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL. Reciprocal changes in tumor antigenicity and antigen-specific t cell function during tumor progression. J Exp Med. 2004;200:1581–1592
  23. Zhao Y, Swenson K, Wekerle T, Rodriguez-Barbosa JI, Arn JS, Sykes M. The critical role of mouse CD4+ cells in the rejection of highly disparate xenogeneic pig thymus grafts. Xenotransplantation. 2000;7:129–137
  24. Schroeder ML. Transfusion associated graft-versus-host-disease. Br J Haematol. 2002;117:275–287
  25. Boranic M, Tonkovic I. Time pattern of the antileukemic effect of graft-versus-host reaction in mice. Cancer Res. 1971;31:1140–1147
  26. Boranic M. Transient graft-versus-host reaction in the treatment of leukemia in mice. J Natl Cancer Inst. 1968;41:421–437
  27. Rubio MT, Kim YM, Sachs T, Mapara M, Zhao G, Sykes M. Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-{gamma}. Blood. 2003;102:2300–2307
  28. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood. 2006;107:628–636
  29. Rubio MT, Saito TI, Kattleman K, Zhao G, Buchli J, Sykes M. Mechanisms of the antitumor responses and host-versus-graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: a critical role for recipient CD4+ T cells and recipient leukocyte infusion-derived IFN-{gamma}-producing CD8+ T cells. J Immunol. 2005;175:665–676
  30. Hanson HL, Donermeyer DL, Ikeda H, et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 2000;13:265–276
  31. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003;198:569–580
  32. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–854
  33. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T- helper and a T-killer cell. Nature. 1998;393:474–478
  34. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480–483
  35. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478–480
  36. Strair RK, Schaar D, Medina D, et al. Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma. J Clin Oncol. 2003;21:3785–3791
  37. Nadler SH, Moore GE. Immunotherapy of malignant disease. Arch Surg. 1969;99:376–381
  38. Sumner WC, Foraker AG. Spontaneous regression of human melanoma: clinical and experimental studies. Cancer. 1960;13:79–81
  39. Teimourian B, McCune WS. Surgical management of malignant melanoma. Am Surg. 1963;29:515–519
  40. Woodruff MF, Nolan B. Preliminary obervations on treatment of advanced cancer by injection of allogeneic spleen cells. Lancet. 1963;13:426–429
  41. Schwarzenberg L, Mathe G, Schneider M, Amiel JL, Cattan A, Schlumberger JR. Attempted adoptive immunotherapy of acute leukaemia by leucocyte transfusions. Lancet. 1966;2:365–368
  42. Porter DL, Connors JM, Van Deerlin VM, et al. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. J Clin Oncol. 1999;17:1234
  43. Ballen KK, Becker PS, Emmons RVB, et al. Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood. 2002;100:442
  44. Yonemoto RH. Adoptive immunotherapy utilizing thoracic duct lymphocytes. Ann N Y Acad Sci. 1976;277:7–19
  45. Medzihradsky J. Modification of tumor homograft immunity during the graft-versus-host reaction. Neoplasma. 1966;13:223–226
  46. Fefer A. Treatment of a Moloney lymphoma with cyclophosphamide and H-2-incompatible spleen cells. Cancer Res. 1973;33:641–644
  47. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333–339
  48. Dey BR, McAfee SL, Sackstein R, et al. Achievement of sustained remissions despite loss of donor chimerism (DC) in patients with chemotherapy-refractory non-Hodgkin's lymphoma (NHL) treated with nonmyeloablative conditioning and allogeneic stem cell transplantation (SCT). Blood. 2001;98:1753
  49. Mokyr MB, Hengst JC, Dray S. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors. Cancer Res. 1982;42:974–979
  50. North RJ. Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol Immunother. 1984;16:175–181
  51. Lehnert S, Rybka WB. Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration. Bone Marrow Transplant. 1994;13:473–477
  52. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest. 2002;110:185–192
  53. Brown IE, Blank C, Kline J, Kacha AK, Gajewski TF. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J Immunol. 2006;177:4521–4529
  54. Katz DH, Davie JM, Paul WE, Benacerraf B. Carrier function in anti-hapten antibody responses. IV. Experimental conditions for the induction of hapten-specific tolerance or for the stimulation of anti-hapten anamnestic responses by “nonimmunogenic” hapten-polypeptide conjugates. J Exp Med. 1971;134:201–223
  55. Blaise D, Bay JO, Faucher C, et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood. 2004;103:435–441
  56. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750–758
  57. Carella AM, Beltrami G, Corsetti MT, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet. 366:318–320.
  58. Ueno NT, Cheng YC, Rondon G, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood. 2003;102:3829–3836
  59. Carnevale-Schianca F, Cignetti A, Capaldi A, et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood. 2006;107:3795–3803
  60. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440
  61. Bregni M, Ueno NT, Childs R. The second international meeting on allogeneic transplantation in solid tumors. Bone Marrow Transplant. 2006;38:527–537
  62. Siddiqui M, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. British Journal of Haematology. 2006;134:596–601
  63. Lissoni P, Brivio F, Fumagalli L, et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers. 2004;19:135–140
  64. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202:907–912
  65. Wrzesinski C, Restifo NP. Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Curr Opin Immunol. 2005;17:195–201
  66. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring t regulatory cells. J Immunol. 2005;174:2591–2601

PII: S1083-8791(08)00072-4

doi: 10.1016/j.bbmt.2008.02.013

Biology of Blood and Marrow Transplantation
Volume 14, Issue 5 , Pages 499-509 , May 2008

Article Tools

* Image Usage & Resolution